NCT05118789: A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 359 planned
- Started
- 4 Jan 2022
- Primary completion
- 31 Dec 2027
- Arms
- Phase 1 dose escalation, Cohort 2a, Cohort 2b, Cohort 2c, Cohort 2d, Cohort 2e
- Results
- None posted
- 12 Nov 2021: Trial registered
- 4 Jan 2022: Trial started